Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs FedEx Corporation (FDX) Price & Performance

BridgeBio Pharma IncTrade
FedEx CorporationTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs FedEx Corporation — how do they compare? BridgeBio Pharma Inc trades at $82.94 (market cap $16.36B), while FedEx Corporation trades at $325.33 (market cap $76.28B). The key difference: FedEx Corporation is far larger — about 4.7× BridgeBio Pharma Inc's market cap, and FedEx Corporation pays a 1.51% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOFDX
Market Cap
$16.36B$76.28B
Sector
HealthIndustrials
52-Week High
$90.17$338.75
52-Week Low
$47.29$180.51
Enterprise Value
$18.14B$105.91B
Dividend Yield
1.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

FedEx Corporation

FedEx (FDX) trades at $325.08, up 2.04% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $360.27 highlight positive momentum. The company's network transformation and focus on premium shipments are driving operational improvements, though revenue has been flat year-over-year. Cash flow trends show a projected rebound in 2026, with net cash flow turning positive.

The outlook for FDX is favorable, supported by cost-cutting initiatives and strategic shifts toward high-margin business. Key risks include competitive pressures and macroeconomic sensitivity. With 57% of analysts rating it a buy and institutional interest growing, the stock presents a compelling opportunity for growth-oriented investors, albeit with exposure to economic cycles.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX